Listing of Claims:

1-31. (cancelled)

32. (new) A compound of formula



(I)

a *N*-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein :

p represents an integer being 0, 1, or 2;

q represents an integer being 0, 1, or 2;

X represents O, S, NR^3 or a direct bond;

R^1 represents hydrogen, hydroxy, halo, amino, C_{1-6}alkyl, C_{1-6}alkyloxy or mono- or di(C_{1-4}alkyl)aminoC_{1-4}alkylamino; in particular, hydrogen, methyl and hydroxy;

R^2 represents oxadiazolyl, thiazolyl, pyrimidinyl or pyridinyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het^2, R^{11} and C_{1-4}alkyl optionally substituted with Het^2 or R^{11};

each R^4 independently represents C_{1-6}alkyl, halo, polyhaloC_{1-6}alkyl or C_{1-6}alkyloxy;

each R^5 independently represents C_{1-6}alkyl, halo or C_{1-6}alkyloxy;

each R^6 independently represents C_{1-6}alkylsulfonyl, aminosulfonyl or phenylC_{1-4}alkylsulfonyl;

each R^7 and each R^8 are independently selected from hydrogen, C_{1-4}alkyl, hydroxyC_{1-4}alkyl, dihydroxyC_{1-4}alkyl, aryl, arylC_{1-4}alkyl, C_{1-4}alkyloxyC_{1-4}alkyl, mono- or di(C_{1-4}alkyl)aminoC_{1-4}alkyl, arylaminocarbonyl, arylaminothiocarbonyl, C_{3-7}cycloalkyl, pyridinylC_{1-4}alkyl, Het^3 and R^6;

R^9 and R^{10} are each independently selected from hydrogen, C_{1-4}alkyl, C_{1-4}alkylcarbonyloxyC_{1-4}alkylcarbonyl, hydroxyC_{1-4}alkylcarbonyl, C_{1-4}alkyloxycarbonylcarbonyl, Het^3aminothiocarbonyl and R^6;

each R^{11} independently being selected from hydroxy, mercapto, cyano, nitro, halo, trihalomethyl, C_{1-4}alkyloxy, carboxyl, C_{1-4}alkyloxycarbonyl, trihaloC_{1-4}alkylsulfonyloxy, R^6, NR^7R^8, $C(=O)NR^7R^8$, aryl, aryloxy, arylcarbonyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkyloxy, phthalimide-2-yl, Het^3 and $C(=O)Het^3$;

R^{12} and R^{13} are each independently selected from hydrogen and C_{1-4}alkyl;

aryl represents phenyl optionally substituted with one, two or three substituents each independently selected from nitro, azido, halo, hydroxy, C_{1-4}alkyl, C_{1-4}alkyloxy, polyhaloC_{1-4}alkyl, NR^9R^{10}, R^6, phenyl, Het^3 and C_{1-4}alkyl substituted with NR^9R^{10};

Het^1 represents a heterocycle selected from a heterocycle selected from imidazolyl, triazolyl, furanyl, oxazolyl, thiazolyl, thiazolinyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, piperidinyl, piperazinyl, triazinyl, benzothiazolyl, benzoxazolyl, purinyl, 1*H*-pyrazolo-[3,4-d]pyrimidinyl, benzimidazolyl, thiazolopyridinyl, oxazolopyridinyl, imidazo-[2,1-b]thiazolyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het^2, R^{11} and C_{1-4}alkyl optionally substituted with Het^2 or R^{11};

Het^2 represents furanyl, thienyl or pyridinyl; wherein said monocyclic heterocycles each independently may optionally be substituted with C_{1-4}alkyl;

Het^3 represents pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl; wherein said monocyclic heterocycles each independently may optionally be substituted with, where possible, one, two or three substituents each independently selected from C_{1-4}alkyl, C_{1-4}alkyloxy, C_{1-4}alkyloxycarbonyl, C_{1-4}alkylcarbonyl, phenylC_{1-4}alkyl, piperidinyl, $NR^{12}R^{13}$ and C_{1-4}alkyl substituted with $NR^{12}R^{13}$.

33. (new) A compound according to claim 32 wherein the 6-azauracil moiety is in the para position relative to the central carbon atom.

34. (new) A compound according to claim 33 wherein q is 1 or 2 and one R^4 substituent is in the 4 position; and p is 1 or 2 and the one or two R^5 substituents are in the ortho position relative to the central carbon atom.

35. (new) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 32.

36. (new) A process for preparing a composition as claimed in claim 35, wherein a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as defined in claim 32.

37. (new) A method for treating one or more of bronchial asthma, atopic dermatitis, allergic-rhinitis or allergic conjunctivitis in a warm-blooded animal in need thereof comprising administering to the warm-blooded animal an effective amount of a compound of claim 32.

38. (new) A method for inhibiting IL-5 production in a warm-blooded animal, comprising administering to the warm-blooded animal an effective amount of a compound of claim 32.